Cellanyx Participates in the 2017 Annual MassBio Conference Panel on Next Generation Diagnostics

Beverly, MA, March 31, 2017 – On Friday, March 31, Cellanyx participated in the 2017 Annual MassBio Conference on a panel discussing Next Generation Diagnostics. The panel discussion was centered around the uphill battle diagnostics companies have faced in achieving investor and payer respect that equates to value relative to their contributions to care. Further, the panel discussed how the next generation of molecular diagnostic companies offer platforms that range from multiplex tumor profiling to DNA and RNA-based liquid biopsies that may provide the ultimate arbitration around cost-effective, life-saving treatment selection. Cellanyx CEO Ashok Chander spoke to the coming shift in attitude towards support of an integrated model of care where next-gen diagnostics will begin to emerge as equals in value and clinical standing to their therapeutic counterparts. Panel participants included:

- **Ashok Chander**, Ph.D., Co-founder & CEO, Cellanyx
- **Patrice Milos**, Ph.D., CEO of Medley Genomics
- **Melanie Nallicheri**, Chief Business Officer, Foundation Medicine
- **Allen Nunnally**, Vice President, Corporate & Business Development/Associate General Counsel
- **Catherine Parham**, Vice President, Clinical Therapeutic Area Head, Shire Pharmaceuticals
- **Walt Carney**, Founder & CEO, Walt Carney Biomarkers Consulting, LLC (Moderator)

Ashok Chander, PhD, CEO of Cellanyx highlighted:

- Genetic heterogeneity has emerged as a key hurdle for next generation diagnostics aimed at early detection, accurate diagnosis, accurate risk assessment / prognosis, and actionable therapy selection.
- Further, localization of the tumor via imaging for accurate biopsy sampling as well as understanding the tumor micro-environment is also a key hurdle to actionable diagnostics.
- Cellanyx is developing and commercializing a first-in-class test that measures dynamic phenotypic (cellular, protein, and RNA-based biomarkers) from living cells derived from biopsy tissue and returns diagnostic results within 72 hours.
- Cellanyx has accrued data on 500-plus patients across five (5) indications: prostate, breast, lung, renal, and bladder cancers
- Using its test, Cellanyx can predict the gold standard of diagnosis – post-surgical adverse pathology – with greater than 85% accuracy with sensitivities and specificities in the upper 80's and mid-90s.

- Cellanyx is positioned to offer its live-cell phenotypic test as a risk stratification and biomarker tool with potential expansion to accelerating the therapeutic clinical trial timeline towards offering a theranostic tool.
- Given current clinical adoption curves, the next generation of diagnostic test are being developed today and there is a huge opportunity to incorporate and synthesize multiple modalities (i.e. phenotypic and genomic information) into powerfully predictive diagnostic tools.

About Cellanyx Diagnostics

Cellanyx Diagnostics is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making. The company's unique 'biopsy-on-a-chip' methodology provides quantitative, actionable assessment of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor aggressiveness and metastatic potential. Cellanyx has demonstrated clinical proof-of-concept with its lead product in development, a diagnostic to improve risk stratification in men with prostate cancer. Learn more at www.cellanyx.com.

###